Jefferson Capital, Inc. (JCAP)
NASDAQ: JCAP · Real-Time Price · USD
16.27
-0.60 (-3.56%)
At close: Aug 1, 2025, 4:00 PM
16.21
-0.06 (-0.37%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Revance Therapeutics Revenue
Jefferson Capital had revenue of $151.32M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $485.04M. In the year 2024, Jefferson Capital had annual revenue of $433.76M with 29.08% growth.
Revenue (ttm)
$485.04M
Revenue Growth
+29.08%
P/S Ratio
2.17
Revenue / Employee
$402,524
Employees
1,205
Market Cap
1.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 433.76M | 97.73M | 29.08% |
| Dec 31, 2023 | 336.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionJCAP News
- 2 months ago - Consumer collections firm Jefferson Capital files for a $100 million IPO - Renaissance Capital
- 2 months ago - Jefferson Capital IPO Registration Document (S-1) - SEC